

<https://helda.helsinki.fi>

Biallelic loss-of-function P4HTM gene variants cause hypotonia, hypoventilation, intellectual disability, dysautonomia, epilepsy, and eye abnormalities (HIDEA syndrome)

Rahikkala, Elisa

2019-10

Rahikkala , E , Myllykoski , M , Hinttala , R , Vieira , P , Nayebyzadeh , N , Weiss , S , Plomp , A S , Bittner , R E , Kurki , M I , Kuismin , O , Lewis , A M , Väisänen , M-L , Kokkonen , H , Westermann , J , Bernert , G , Tuominen , H , Palotie , A , Aaltonen , L , Yang , Y , Potocki , L , Moilanen , J , van Koningsbruggen , S , Wang , X , Schmidt , W M , Koivunen , P & Uusimaa , J 2019 , ' Biallelic loss-of-function P4HTM gene variants cause hypotonia, hypoventilation, intellectual disability, dysautonomia, epilepsy, and eye abnormalities (HIDEA syndrome) ' , Genetics In medicine , vol. 21 , no. 10 , pp. 2355-2363 . <https://doi.org/10.1038/s41436-019-0503-4>

<http://hdl.handle.net/10138/306749>

<https://doi.org/10.1038/s41436-019-0503-4>

cc_by_nc_sa

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Biallelic loss-of-function *P4HTM* gene variants cause hypotonia, hypoventilation, intellectual disability, dysautonomia, epilepsy, and eye abnormalities (HIDEA syndrome)

Elisa Rahikkala, MD, PhD^{1,2}, Matti Myllykoski, PhD^{3,4}, Reetta Hinttala, PhD^{1,3}, Päivi Vieira, MD, PhD^{1,5}, Naemeh Nayebyzadeh, MSc^{1,3}, Simone Weiss, MD⁶, Astrid S. Plomp, MD⁷, Reginald E. Bittner, MD⁸, Mitja I. Kurki, PhD^{9,10,11}, Outi Kuismin, MD, PhD^{1,2,11}, Andrea M. Lewis, MS^{12,13}, Marja-Leena Väisänen, PhD¹⁴, Hannaleena Kokkonen, PhD¹⁴, Jonne Westermann, MD⁷, Günther Bernert, MD⁶, Hannu Tuominen, MD, PhD¹⁵, Aarno Palotie, MD, PhD^{9,10,11,16,17}, Lauri Aaltonen, MD, PhD¹⁸, Yaping Yang, PhD^{13,19}, Lorraine Potocki, MD^{12,13}, Jukka Moilanen, MD, PhD^{1,2}, Silvana van Koningsbruggen, PhD⁷, Xia Wang, PhD^{13,19}, Wolfgang M. Schmidt, PhD⁸, Peppi Koivunen, MD, PhD^{3,4} and Johanna Uusimaa, MD, PhD^{1,3,5}

Purpose: A new syndrome with hypotonia, intellectual disability, and eye abnormalities (HIDEA) was previously described in a large consanguineous family. Linkage analysis identified the recessive disease locus, and genome sequencing yielded three candidate genes with potentially pathogenic biallelic variants: transketolase (*TKT*), transmembrane prolyl 4-hydroxylase (*P4HTM*), and ubiquitin specific peptidase 4 (*USP4*). However, the causative gene remained elusive.

Methods: International collaboration and exome sequencing were used to identify new patients with HIDEA and biallelic, potentially pathogenic, *P4HTM* variants. Segregation analysis was performed using Sanger sequencing. P4H-TM wild-type and variant constructs without the transmembrane region were overexpressed in insect cells and analyzed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blot.

Results: Five different homozygous or compound heterozygous pathogenic *P4HTM* gene variants were identified in six new and six

previously published patients presenting with HIDEA. Hypoventilation, obstructive and central sleep apnea, and dysautonomia were identified as novel features associated with the phenotype. Characterization of three of the P4H-TM variants demonstrated yielding insoluble protein products and, thus, loss-of-function.

Conclusions: Biallelic loss-of-function *P4HTM* variants were shown to cause HIDEA syndrome. Our findings enable diagnosis of the condition, and highlight the importance of assessing the need for noninvasive ventilatory support in patients.

Genetics in Medicine (2019) 21:2355–2363; <https://doi.org/10.1038/s41436-019-0503-4>

Keywords: P4HTM; exome sequencing; HIDEA syndrome; intellectual disability; hypoventilation

INTRODUCTION

Prolyl 4-hydroxylases (P4Hs) are key enzymes in the synthesis of collagens and the regulation of oxygen homeostasis.^{1–3} Previously, variants in the *P4HA2* (OMIM 600608) encoding collagen prolyl 4-hydroxylase (C-P4H) α -2 subunit have been associated with nonsyndromic high myopia (OMIM 617238),⁴ and variants in the *P4HB* (OMIM 176790) encoding prolyl 4-hydroxylase β -subunit have been associated

with Cole–Carpenter syndrome (OMIM 112240),⁵ while variants in the *EGLN1* (OMIM 606425) coding for a hypoxia-inducible factor (HIF) isoenzyme HIF-P4H/PHD2 have been associated with familial erythrocytosis and high altitude adaptation hemoglobin.^{6–9} A transmembrane prolyl 4-hydroxylase (P4H-TM) is encoded by the *P4HTM* gene (OMIM 614584), which has not yet been unequivocally linked to any Mendelian disorder. P4H-TM has its highest

Correspondence: Elisa Rahikkala (elisa.rahikkala@ppshp.fi). *Affiliations are listed at the end of the paper.

Shared last author: Peppi Koivunen and Johanna Uusimaa

Shared second last author: Silvana van Koningsbruggen, Xia Wang and Wolfgang M. Schmidt

Submitted 24 November 2018; accepted: 18 March 2019

Published online: 3 April 2019

expression in the brain and eye,^{10,11} and it participates in the oxygen-dependent regulation of the hypoxia-inducible factor (HIF). The normal functioning of P4H-TM has been assessed to be crucial for normal vision and renal function in mice.¹² However, the relevance of P4H-TM to human disease remains to be clarified.

In a previous study, we identified a large Finnish family with multiple affected family members presenting with a syndromic form of severe cognitive impairment.¹³ All the affected individuals had profound intellectual disability, hypotonia, and strabismus; we proposed the acronym HIDEA (hypotonia, intellectual disability, and eye abnormalities) for this condition. Our study identified a recessive disease locus in the chromosomal region 3p22.1-3p21.1. However, because all affected individuals carried potentially pathogenic biallelic variants in three genes, *P4HTM*, *TKT*, and *USP4*, segregating with the disease, the causative gene remained elusive.

In the current study, we report seven novel patients from four unrelated families presenting with HIDEA. DNA was available from six patients who carried potentially pathogenic biallelic *P4HTM* gene variants. One of the patients carried the same previously published homozygous potentially pathogenic variants in *P4HTM*, *TKT*, and *USP4* genes. Five of the patients had novel homozygous or compound heterozygous variants only in the *P4HTM* gene, thereby indicating that *P4HTM* is the causative gene. Variant characterization demonstrated that the variants yield an insoluble protein product. In summary, we present robust evidence that HIDEA is caused by biallelic pathogenic *P4HTM* gene variants, and delineate the clinical characteristics of this syndrome.

MATERIALS AND METHODS

We conducted clinical and molecular genetic studies on seven patients from four families presenting with the phenotype resembling previously described patients with HIDEA syndrome.¹³ Patients were enrolled in the study from four centers (Clinic for Children and Adolescents, Oulu University Hospital, Oulu, Finland; Texas Children's Hospital, Houston, TX; Kaiser Franz Josef Hospital with G.v. Preyer Children's Hospital, Vienna, Austria; Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands). Novel patients were recruited in the study based on the clinical phenotypes and biallelic potentially pathogenic *P4HTM* variants in patients resembling patients with HIDEA syndrome previously described by Kaasinen *et al.*, which allowed clinicians and relatives of patients with HIDEA syndrome and biallelic potentially pathogenic *P4HTM* variants to contact the corresponding author (L.A.).¹³ Furthermore, we re-evaluated the patients of the previously published study.¹³ Written informed consent was obtained from all the parents or guardians of the patients participating in this study, including permission to publish photos. The study was approved by the ethics committees of the Northern Ostrobothnia Hospital District at the Oulu

University Hospital and Baylor College (Houston, TX) (for family 2).

Molecular genetic studies

We extracted genomic DNA from peripheral blood or buccal swab samples of the probands, their affected siblings, and their parents using standard methods. We performed exome sequencing (ES) at the Broad Institute of MIT and Harvard (Cambridge, MA) for family 1; at the Baylor Genetics Laboratory (Houston, TX) for family 2; at the Neuromuscular Research Department, Medical University of Vienna, Austria, for family 3; and at the Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, for family 4. Segregation of *P4HTM* variants within the families was confirmed by Sanger sequencing. More details on ES analyses are provided in the Supplementary Note including detailed clinical data.

Characterization of P4H-TM variants

Fibroblasts and myoblasts from healthy control individuals were cultured, RNA was isolated, and reverse transcription polymerase chain reaction (RT-PCR) was performed to identify the transcript variants for P4H-TM, as described in the Supplementary Note.

P4H-TM variants were generated to the pVL1392-P4H-TM⁸⁸⁻⁵⁰² construct¹⁰ using routine PCR with appropriate primers (available on request). To generate the baculoviruses, variant constructs were transfected into *Sf9* cells in the presence of flashBAC DNA with baculofECTIN II transfection reagent (Oxford Expression Technologies) according to the flashBAC transfection protocol. Transfection of the wild-type construct has been described previously.¹⁰ Baculovirus stocks were amplified twice, and the amplified virus stocks were used to infect *Sf9* cells grown as adherent culture on 10-cm tissue culture plates in complete TNM-FH insect cell media (Sigma-Aldrich). Cells were harvested 72 hours after infection, washed with phosphate buffer saline (PBS), and stored at -80 °C until use.

For lysis, the cells were thawed, resuspended, and homogenized in 5 ml lysis buffer containing 10 mM Tris-HCl pH 7.8, 100 mM glycine, 150 mM NaCl, 20 mM imidazol, 2 mM CaCl₂, 20 μM FeSO₄, 0.1% Triton X-100, and 1X Complete EDTA-free protease inhibitor (Roche). The insoluble and soluble fractions were separated with a 15-minute centrifugation at 20,000 × *g* at 4 °C. Cell pellets were washed twice with 5 ml lysis buffer and centrifuged again after each wash. The supernatants with soluble fractions were pooled together. Finally, the cell pellet was resuspended in 5 ml of lysis buffer, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) samples were prepared of the insoluble and soluble fractions. Two 10% SDS-PAGE gels were run parallel to each other and a threefold excess of the soluble sample versus the insoluble sample was loaded to take into account the increased volume from the washes. Further, one of the gels was stained with Coomassie, while the other was transferred

overnight (4 °C, 30 V) to a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked, incubated for two hours (4 °C) with 1:10,000 dilution of rabbit anti-P4H-TM antibody,¹⁰ and for one hour (4 °C) with 1:5000 dilution of HRP-conjugated goat antirabbit antibody (Dako Denmark A/S, Glostrup, Denmark). Finally, the membrane was incubated for one minute with Pierce ECL Western Blotting Substrate (Thermo Scientific) and for three minutes with Amersham Hyperfilm ECL (GE Healthcare).

Analyses of skeletal muscle biopsy and autopsy samples

As a part of clinical diagnostics, skeletal muscle biopsy samples had previously been taken from 3 of 13 patients due to suggested neurometabolic disease. Histology and histochemistry on skeletal muscle samples (patients 1, 2, and 5) and autopsy tissue samples (patient 13) were performed using standard methods. Further, the activities of mitochondrial respiratory chain enzyme complexes were determined from skeletal muscle biopsy samples, as described previously.¹⁴

RESULTS

Clinical delineation of the patients with *P4HTM* variants

Clinical findings of patients 1–7 compared with an update of the previously described patients¹³ are compiled in Table 1. Eight patients are currently alive (current age between 3 and 55 years), and five are deceased (age at death between 7 months and 61 years). Nine patients are male, and four are female. All the patients have hypotonia ($N = 13/13$), and either intellectual disability ($N = 12/13$) or developmental delay (1/13, patient 4 who died at the age of 7 months). Furthermore, the common presenting features include strabismus ($N = 11/13$, 85%), epilepsy ($N = 10/13$, 77%), and central or obstructive sleep apnea ($N = 8/13$, 62%). Nine patients have a medical history of pneumonia or recurrent pneumonias ($N = 9/13$, 69%). Four patients have had respiratory distress and required respiratory support during pneumonias, and three patients died during pneumonia or other respiratory tract infections. Some patients also show dysautonomia, including constipation ($N = 6/13$, 46%), recurrent hypothermia or hyperthermia ($N = 4/13$, 31%), and reduced sweating ($N = 2/13$, 15%). Further, some patients have suspected recurrent parasomnias ($N = 4/13$, 31%). Six patients ($N = 6/13$, 46%) have a body mass index (BMI) over 25 kg/m². Two patients ($N = 2/4$, 50%) had advanced bone age at the age of 8 years. Brain magnetic resonance image (MRI) is normal in most patients.

Detailed clinical descriptions of the patients are provided in the Supplementary Note. The characteristic gait of patients 2, 3, 8, 10, and 11 is demonstrated in Supplementary Videos 1–5.

Histopathological and biochemical findings of skeletal muscle samples and brain autopsy sample

The muscle biopsy of patient 1 showed low activity of mitochondrial respiratory chain complex III. In addition, the

muscle biopsy of patient 2 was suggestive of a mitochondrial, neurometabolic disease. Electron microscopy indicated increased mitochondria, with some that were enlarged and abnormally shaped. Mitochondrial respiratory chain activities revealed a decrease in complexes I–IV. Furthermore, the muscle biopsy of patient 5 showed an increased variability of muscle fiber diameters, hypertrophied muscle fibers, scattered small atrophied fibers, and basophilic muscle fibers (Supplementary Fig. 1). The muscle biopsy sample of patient 13, taken during autopsy, showed unspecific type 2 muscle fiber atrophy (Supplementary Fig. 2A) and COX-negative fibers suggestive of mitochondrial pathology. In addition to these findings in skeletal muscle samples, two patients (patients 1 and 13) had mild fatty degeneration of liver. Patient 13's autopsy also revealed that the cerebellum was atrophic, and histologically there was both loss and degeneration of Purkinje cells (Supplementary Fig. 2B).

Analysis of the *P4HTM* gene

All seven Finnish patients (family 1, patient 1 and family 5, patients 8–13) had a homozygous *P4HTM* gene variant c.1073G>A (NM_177938.2, GRCh38 g.3:49005046G>A, rs182812551). While this variant is predicted to cause a missense change in the canonical transcript, which was not expressed in fibroblasts and myoblasts, it creates an in-frame loss of complete exon 6 of the main transcript (NM_177939.2) on the RNA level (r.888_1073del).¹³ The parents of the patients were heterozygous carriers of the variant. The variant is present in the Genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org/variant/3-49042479-G-A>) database with a minor allele frequency (MAF) of 9.75×10^{-5} ; the allele frequency is 20× higher in Finland (7.8×10^{-4}) than in non-Finnish Europeans (4×10^{-5}), and there are no homozygous individuals.

Two brothers of family 2, patients 2 and 3, were compound heterozygous for the *P4HTM* gene c.482A>C; p.(His161Pro) (NM_177938.2, GRCh38 g.3:49001483A>C) and c.286dupC; p.(Gln96Profs*29) (NM_177938.2, GRCh38 g.3:48990542dupC) variants. The father was a heterozygous carrier of the *P4HTM* gene c.286dupC; p.(Gln96Profs*29) variant and the mother was a heterozygous carrier of the *P4HTM* gene c.482A>C; p.(His161Pro) variant. The healthy sister was heterozygous for the *P4HTM* gene c.482A>C; p.(His161Pro) variant and negative for the c.286dupC; p.(Gln96Profs*29) variant.

Two brothers of family 3, patients 5 and 6, were homozygous for the c.1594C>T; p.(Gln532*) (NM_177938.2, GRCh38 g.3:49006809C>T) variant. Their parents were heterozygous carriers. No DNA was available from patient 4, who presented with a similar clinical phenotype as his affected siblings.

Trio ES analysis of patient 7 (family 4) and his parents revealed that the patient had a homozygous variant in the *P4HTM* gene c.949delG (NM_177938.2, GRCh38 g.3:49004922delG). The parents carried this variant in a heterozygous state. This deletion predicts a frameshift change

Table 1 Clinical characteristics of patients with pathogenic biallelic *P4H7M* variants

	Family 1 Patient 1	Family 2 Patient 2	Patient 3	Family 3 Patient 4	Patient 5	Patient 6
Reference	This report	This report	This report	This report	This report	This report
Outcome	Died (5 years)	Alive at 18 years	Alive at 13 years	Died (7 months)	Died (8 years)	Alive at 3 years
Gender	Female	Male	Male	Male	Male	Male
Growth parameters						
Height (cm)	114 cm, 90th percentile	178 cm, 59th percentile	147 cm, 32nd percentile	50th percentile	134 cm, 50th percentile	96.5 cm, 50th percentile
Weight (kg)	42 kg, 99th percentile	90 kg, 94th percentile	40 kg, 41st percentile	In normal range	24 kg, 10th percentile	15 kg, 70th percentile
BMI	32 kg/m ²	28 kg/m ²	18 kg/m ²	No failure to thrive	13.4 kg/m ²	16.3 kg/m ²
OFC (cm)	53 cm, 85th percentile	58 cm, 91st percentile	54 cm, 50th percentile	In normal range	49.5 cm, <3rd percentile	47 cm, <3rd percentile
Neurologic features						
Hypotonia	+	+	+	++	++	++
Independent walking	+	+	+	-	-	-
Language development	Simple sentences	Simple sentences	No speech	NA	No speech	No speech
Severity of intellectual disability	Severe	NA	NA	NA	Profound	Profound
Epilepsy	+	-	+	+	+	+
EEG	Slow background activity, ictal epileptiform discharges close to the midline	Diffuse disturbance, generalized sharp and wave discharges	Epileptiform activity during sleep	NA	Multifocal spikes, theta-delta activity	Multifocal spikes
Respiratory problems						
Obstructive sleep apnea	+	+	+	NA	-	-
Central sleep apnea	-	+	+	+	+	+
BiPAP or HFNC oxygen therapy	-	BiPAP at nights	BiPAP at nights	NA	BiPAP at nights	HFNC
Other respiratory problems	Sudden death at night during a respiratory tract infection	Bradypnea	Bradypnea	Bradypnea, sudden death during first febrile respiratory infection	Bradypnea, respiratory rate cannot adapt to metabolic need	Bradypnea, respiratory rate cannot adapt to metabolic need
Sleep behavior disorder	-	-	+	-	-	-
Ophthalmological features						
Strabismus	Alternating exotropia, vertical deviation	Alternating exotropia	Intermittent alternating exotropia	-	Alternating exotropia, vertical deviation	Alternating exotropia, vertical deviation
Other ophthalmological abnormalities	Hyperopia, amblyopia in the left eye, optic atrophy	Refractive amblyopia	Strabismus amblyopia, cortical blindness	Abnormal eye movements	Achromic fundi	-
Other						
Infections	Recurrent pneumonias	Viral pneumonias requiring respiratory support	Viral pneumonias requiring respiratory support	Died during first pneumonia	Recurrent pneumonias until age 3 years	Recurrent pneumonias
Dysautonomia of thermoregulation	-	-	Recurrent hypothermia	-	Recurrent hyperthermia, reduced sweating	Recurrent hyperthermia, reduced sweating
Constipation	-	-	+	-	-	-
Bone age	NA	Advanced	NA	NA	NA	NA
Family 4 Patient 7	Family 5 Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
This report	Kaasinen et al.	Kaasinen et al.	Kaasinen et al.	Kaasinen et al.	Kaasinen et al.	Kaasinen et al.
Died (7 months)	Alive at 31 years	Alive at 29 years	Alive at 18 years	Alive at 21 years	Alive at 55 years	Died (61 years)
Male	Male	Female	Male	Male	Female	Female

Table 1 continued

Family 5		Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13
Patient 7		160 cm, <3rd percentile	163 cm, 28th percentile	166 cm, 5th percentile	161.5 cm, <3rd percentile	150 cm, <3rd percentile	140 cm, <3rd percentile
64 cm, 50th percentile							
6.7 kg, 80th percentile		62 kg, 20th percentile	57 kg, 48th percentile	76 kg, 74th percentile	76 kg, 67th percentile	58 kg, 51st percentile	55 kg, 36th percentile
NA		24.2 kg/m ²	21.4 kg/m ²	27.6 kg/m ²	29.1 kg/m ²	25.8 kg/m ²	27.8 kg/m ²
42 cm, 55th percentile		NA	58 cm, 96th percentile	57.6 cm, 65th percentile	60 cm, 95th percentile	56 cm, 65th percentile	NA
++	+	+	+	+	+	+	+
-	+	-	-	-	-	-	-
NA	Simple sentences	No speech	No speech	No speech	No speech	No speech	No speech
Profound	Profound	Profound	Profound	Profound	Profound	Profound	Profound
+	-	+	+	+	-	+	+
Focal abnormalities	Monotonic and slow background activity, no epileptiform changes	Strong background abnormality and intermittent epileptiform sharp waves	NA	Background abnormality, epileptiform activity	Slow background activity, no irritative features	NA	NA
-	-	NA	NA	+	+	NA	NA
-	-	NA	NA	-	+	NA	NA
BIPAP	-	-	-	BIPAP at nights	BIPAP at nights	-	-
Hypoventilation	-	-	-	-	Chronic hypoventilation, respiratory distress during a pneumonia	Respiratory distress requiring ventilator support during pneumonias	Died at the age of 61 years, autopsy showed acute pneumonia
+	+	-	-	-	+	-	-
-	Alternating exotropia	Alternating exotropia	Alternating exotropia	Alternating exotropia, vertical deviation	Alternating exotropia and vertical deviation	Alternating exotropia	Exotropia
Rotating eye movements	Myopia, rotatory nystagmus, achromic fundi	Hyperopia, achromic fundi	Hyperopia, achromic fundi	Hyperopia, achromic fundi, dermoid in the left eye	Hyperopia, astigmatismus, temporally achromic fundi	Keratoconus and eyelid entropium in the right eye	-
-	Recurrent otitis media as adult	-	-	-	Recurrent otitis media, pneumonia requiring ventilator support and tracheostomy	Recurrent pneumonias, left lung pleurectomy due to pleural empyema	Recurrent urinary tract infections, died during pneumonia
-	-	Recurrent hypothermia	-	-	-	-	-
+	+	+	+	-	+	-	+
NA	Advanced	Normal	Normal	Normal	NA	NA	NA

BIPAP bilevel positive airway pressure, BMI body mass index, EEG electroencephalogram, HFNC high flow nasal cannula, NA not available, OFC occipital frontal circumference.




Fig. 1 Pedigrees and Sanger validation and segregation of the identified *P4HTM* variants. (a) The segregation of the *P4HTM* c.1073G>A variant (NM_177938.2) in family 1. The protein defect of the biologically active main transcript is given in parenthesis (NM_177939.2). (b) The segregation of the compound heterozygous *P4HTM* c.286dupC; p.(Gln96Profs*29) and c.482A>C; p.(His161Pro) variants (NM_177938.2) in family 2. (c) The segregation of the *P4HTM* c.1594C>T; p.(Gln532*) variant (NM_177938.2) in family 3. (d) The segregation of the *P4HTM* c.949delG; p.(Val317Phefs*30) variant (NM_177938.2) in family 4. (e) Facial figure of patient 1 (F1:II.3) shows facial hypotonia with tented upper lip vermillion and open mouth posture, a round face, and strabismus. (f) Facial figure of patient 2 (F2:II.1) shows hypotonic/myopathic facial appearance with a tented upper lip vermillion and open mouth posture. (g) Facial figure of patient 3 (F2:II.3) shows marked facial hypotonia with open mouth posture, giving a myopathic facial appearance. (h) Depiction of the *P4HTM* protein and location of the variants identified in the four families.

in the protein. Valine at position 317 is the first affected amino acid, with a premature stop codon after 28 amino acids p.(Val317Phefs*30). Frameshift variants creating a premature stop codon yield a shorter protein or no protein at all.

The pedigrees, identified variants, and their location in the protein are illustrated in Fig. 1. The genetic findings are described in Supplementary Table 1.

Characterization of the variants

Previously, we characterized *in vitro* recombinant P4H-TM^{88–502} of the 502-residue noncanonical isoform, which lacks the transmembrane domain expressed in insect cells.¹⁰ Our RT-PCR analyses suggested that the 502-residue variant is the major transcript expressed from human-derived cells (Supplementary Fig. 3); therefore, we used it here to separately generate the variants corresponding to p.His161Pro, p.Gln532* and p.Arg296Ser;Val297_Arg358del on this backbone and expressed these variants in insect cells along with wild-type P4H-TM^{88–502}. All variants yielded a recombinant enzyme analyzed using SDS-PAGE and Coomassie blue or western blotting (Fig. 2). However, the fraction of soluble protein was severely reduced for the p.Gln532* variant and completely abolished for the p.His161Pro and p.Arg296Ser;Val297_Arg358del variants (Fig. 2). Despite the lack of the C-terminal endoplasmic reticulum retention signal Arg-Val-Glu-Leu in the p.Gln532* variant, we were unable to detect it in the expression medium at the end of the 72-hour




Fig. 2 P4H-TM wild-type (WT) and variant enzymes were over-expressed in insect cells and analyzed with sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting. Cells were lysed and the proteins were separated into insoluble (IS) and soluble (S) fractions. Both fractions of WT and variant enzymes p.His161Pro, p.Gln532*, and p.Arg296Ser;Val297_Arg358del (Ex6del) were loaded on 10% SDS-PAGE, and the gels were either stained with Coomassie blue (top) or western blotting against P4H-TM (bottom).

expression period (data not shown). The *P4HTM* variants studied here reside in different parts of the polypeptide and represent different types of variants. Despite these differences, the outcome is very similar. Although no structural data is available on P4H-TM, the insolubility of the variants suggests improper folding of the proteins. Together, these data suggest

that the variants identified in the patients cause loss of function of P4H-TM.

DISCUSSION

In this study, we report seven new patients from four unrelated families and a clinical update of a large previously published consanguineous family with HIDEA syndrome caused by biallelic *P4HTM* variants. The phenotype is characterized by muscular and central hypotonia, hypoventilation, intellectual disability, dysautonomia, epilepsy, and eye abnormalities (HIDEA). Variant characterization demonstrates that the variants affect protein folding by yielding an insoluble protein product.

P4H-TM has a broad expression pattern, with the highest expression levels in the brain and eye. All the patients with *P4HTM* gene variants have developmental delay or intellectual disability and visual abnormalities—such as strabismus, rotating eye movements, nystagmus, or cortical blindness—thereby suggesting that P4H-TM is crucial for the functioning of the normal human brain as well as the visual tract. Muscle biopsy samples from four patients demonstrate increased variability of the muscle fiber diameters, mild type 2 muscle fiber atrophy and COX-negative fibers, and decreased mitochondrial respiratory chain enzyme activities in two patients, thereby suggesting that a defect in P4H-TM may also disrupt normal mitochondrial function. The autopsy of a 61-year-old patient with the homozygous c.1073G>A variant revealed loss and degeneration of Purkinje cells, which could be caused by a long-term undiagnosed hypoventilation and/or neurodegeneration based on progressive neurodegenerative diseases.

P4H-TM knockout mice reveal overlapping phenotypic features with HIDEA patients with biallelic *P4HTM* variants, such as retinal defects causing vision impairment,¹² thereby suggesting that loss-of-function is the possible underlying mechanism. Further, mouse studies suggest that P4H-TM is necessary for normal visual and renal function.¹² As mentioned above, the patients exhibit various visual abnormalities, such as congenital nystagmus, strabismus, rotating eye movements, achromic retinal fundi, and cortical blindness. However, patients with *P4HTM* gene variants did not show any evidence of structural kidney abnormalities or albuminuria indicative of decreased kidney function, even at an older age.

In addition to the previously described combination of symptoms, this study reveals hypoventilation, including obstructive and central sleep apnea, dysautonomia, and an increased tendency to develop respiratory distress during pneumonias as novel characteristic clinical features of HIDEA patients. Several patients have BiPAP dependency at night due to central and obstructive sleep apnea or hypoventilation especially during respiratory infections requiring respiratory support. Four patients (4/13, 31%) had infantile onset tendency to respiratory insufficiency and respiratory arrest resulting in infantile or childhood death of

three of them. There is heterogeneity in the clinical presentation of patients even with exactly the same pathogenic biallelic *P4HTM* variants suggesting that the disease severity is modified by additional genetic and environmental factors.

Further, we found that the *P4HTM* c.1073G>A variant creates an in-frame loss of exon 6 from the messenger RNA (mRNA) of the 502-residue transcript variant 1 (NM_177939.2), which yields an insoluble protein product. This is consistent with the latest research findings that pathogenic variants altering protein code often disrupt splicing.¹⁵ Interestingly, the noncanonical transcript (NM_177939.2) coding for the 502-residue protein was the prevalent transcript variant expressed in normal human fibro- and myoblasts instead of the canonical transcript (NM_177938.2) yielding a 563-residue protein. Theoretically, the canonical transcript coding for the 563-residue protein could be expressed in brain tissue, which is critical for HIDEA syndrome, but we do not have any experimental evidence to prove this. In northern blot analysis in brain the major *P4HTM* mRNA species was 2.3 kb, unlike in all other tissue studied, where it was 1.8 kb,¹⁰ which may indicate that in the brain the canonical transcript is expressed. Both transcripts have nine exons, but the transcript coding for the 502-residue protein excludes parts of exons 6 and 7. All the pathogenic variants identified in this study located in areas of the *P4HTM* sequence present in both transcripts, and it is currently unknown whether HIDEA syndrome could be caused by biallelic pathogenic variants located in parts of exons 6 or 7 that are not present in the transcript coding for the 502-residue protein.

P4H-TM was originally suggested to be a fourth HIF-P4H,¹⁶ although it was later reported to be more closely homologous to the C-P4Hs.¹⁰ Unlike neither of the previously characterized P4Hs, it has an N-terminal EF-hand motif¹⁶ that is implicated in calcium binding. Recombinant P4H-TM did not hydroxylate in vitro type I collagen polypeptide but it hydroxylated HIF1 α .¹⁰ Its downregulation by small interfering (siRNA) stabilized HIF α ,¹⁰ and its genetic knockout in mice associated with induction of renal erythropoietin expression similarly to inhibition of HIF-P4Hs.¹⁷ In cortical neurons genetic deficiency of P4H-TM stabilized HIF1 α under normoxia, and in tissues with high endogenous P4H-TM expression level, such as brain, eye, and kidney, the expression of certain HIF target genes was more upregulated in hypoxia compared with wild-type mice.¹² However, its location having the catalytic domain within the endoplasmic reticulum lumen, and its ability to also hydroxylate to a low extent HIF α polypeptide, where the HIF-P4H prolines were mutated to alanines, would suggest it may have other substrates than HIF α .¹⁰ The only known genetic variants of any HIF-P4H are those for HIF-P4H-2, the most abundant isoenzyme whose inhibition alone stabilizes HIF α ³ that associate with erythropoiesis. As these variants did not cause a complete loss-of-function, and some even had a gain-of-

function phenotype, it may be that complete loss of HIF-P4H-2 catalytic activity, which would result in a full-powered HIF response, is not tolerable in humans, similarly to mice.¹⁸ Therefore direct comparison of the phenotype of the loss-of-function *P4HTM* variants characterized here to regulation of the hypoxia response is not feasible.

Autosomal recessive inheritance is estimated to have a small contribution in the etiology of intellectual disability in outbred populations.¹⁹ Northern Finland is a known genetic isolate, where the current population has arisen from a small number of founder families, and enrichment of rare recessive gene variants has been demonstrated in this young population.²⁰ All the Finnish patients in this study had the same variant in the *P4HTM*, thereby suggesting a founder effect.²¹ Homogeneous populations, such as the Finnish population, that share long segments of linkage disequilibrium are useful in mapping the causative locus of a monogenic disease; however, the homogeneous genetic background hinders the identification of the actual disease-causing gene as multiple variants in different genes in the same locus may cosegregate with the disease. In contrast, heterogeneous populations with marked genetic variability facilitate in underpinning the causative gene and broaden the knowledge of the full phenotypic spectrum caused by a specific gene. Studying patients with the same monogenic syndrome from different ethnic backgrounds has repeatedly revealed novel disease-causing genes. International collaborations may enable the identification of the causative gene and the delineation of the phenotype even in very rare childhood heritable diseases.²²

In conclusion, we report seven new patients with the HIDEA syndrome and demonstrate that the phenotype in this cohort of patients is strikingly similar to the previously studied patients with the syndrome. Genetic analysis identified recessively inherited intragenic *P4HTM* variants as an underlying cause of the syndrome. Variant characterization suggested that the identified variants cause loss of function of P4H-TM. Novel, previously undescribed features include hypoventilation (most pronounced during respiratory infections), central and obstructive sleep apnea, and dysautonomia. This indicates the importance of performing polysomnography in patients with biallelic pathogenic *P4HTM* variants and assessing the possible need for noninvasive ventilatory support to prevent sudden death. Our results demonstrate that biallelic loss-of-function *P4HTM* gene variants cause HIDEA, and greatly facilitate the diagnosis and management of this challenging condition.

SUPPLEMENTARY INFORMATION

The online version of this article (<https://doi.org/10.1038/s41436-019-0503-4>) contains supplementary material, which is available to authorized users.

ACKNOWLEDGEMENTS

We thank all the families that participated in this study. Further, we acknowledge Pirjo Keränen, BCO sequencing core, for excellent technical assistance. This study was supported by the Academy of Finland Grants 266719 and 308009, the S. Jusélius Foundation, the Emil Aaltonen Foundation, and the Jane and Aatos Erkkö Foundation to P.K. We also thank the Scribendi proofreading team for language editing.

DISCLOSURE

X.W. and Y.Y.: The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular genetic testing offered at Baylor Genetics. The other authors declare no conflicts of interest.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. *Ann Med*. 2008;40:402–417.
2. Myllyharju J. Prolyl 4-hydroxylases, master regulators of the hypoxia response. *Acta Physiol (Oxf)*. 2013;208:148–165.
3. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell*. 2008;30:393–402.
4. Guo H, Tong P, Liu Y, et al. Mutations of P4HA2 encoding prolyl 4-hydroxylase 2 are associated with nonsyndromic high myopia. *Genet Med*. 2015;17:300–306.
5. Rauch F, Fahiminiya S, Majewski J, et al. Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB. *Am J Hum Genet*. 2015;96:425–431.
6. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. *Proc Natl Acad Sci USA* 2006;103:654–659.
7. Percy MJ, Furlow PW, Beer PA, et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. *Blood*. 2007;110:2193–2196.
8. Ladrone C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. *N Engl J Med*. 2008;359:2685–2692.
9. Lorenzo FR, Huff C, Myllymäki M, et al. A genetic mechanism for Tibetan high-altitude adaptation. *Nat Genet*. 2014;46:951–956.
10. Koivunen P, Tiainen P, Hyvärinen J, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. *J Biol Chem*. 2007;282:30544–30552.
11. Hyvärinen J, Parikka M, Sormunen R, et al. Deficiency of a transmembrane prolyl 4-hydroxylase in the zebrafish leads to basement membrane defects and compromised kidney function. *J Biol Chem*. 2010;285:42023–42032.
12. Leinonen H, Rossi M, Salo AM, et al. Lack of P4H-TM in mice results in age-related retinal and renal alterations. *Hum Mol Genet*. 2016;25:3810–3823.
13. Kaasinen E, Rahikkala E, Koivunen P, et al. Clinical characterization, genetic mapping and whole-genome sequence analysis of a novel autosomal recessive intellectual disability syndrome. *Eur J Med Genet*. 2014;57:543–551.
14. Hautakangas M-R, Hinttala R, Rantala H, et al. Evaluating clinical mitochondrial respiratory chain enzymes from biopsy specimens presenting skewed probability distribution of activity data. *Mitochondrion*. 2016;29:53–58.
15. Soemedi R, Cygan KJ, Rhine CL, et al. Pathogenic variants that alter protein code often disrupt splicing. *Nat Genet*. 2017;49:848–855.
16. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. *Biochem Biophys Res Commun*. 2002;296:343–349.

17. Laitala A, Aro E, Walkinshaw G, et al. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. *Blood*. 2012;120:3336–3344.
18. Takeda K, Ho VC, Takeda H, et al. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. *Mol Cell Biol*. 2006;26:8336–8346.
19. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet*. 2012;380:1674–1682.
20. Lim ET, Würtz P, Havulinna AS, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet*. 2014;10:e1004494.
21. Norio R, Finnish Disease, Heritage I. characteristics, causes, background. *Hum Genet*. 2003;112:441–456.
22. Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases. *Am J Hum Genet*. 2017;100:695–705.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>.

© The Author(s) 2019

¹PEDEGO Research Unit and Medical Research Centre Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland. ²Department of Clinical Genetics, Oulu University Hospital, Oulu, Finland. ³Biocenter Oulu, University of Oulu, Oulu, Finland. ⁴Faculty of Biochemistry and Molecular Medicine, Oulu Centre for Cell-Matrix Research, University of Oulu, Oulu, Finland. ⁵Department of Children and Adolescents, Division of Paediatric Neurology, Oulu University Hospital, Oulu, Finland. ⁶Kaiser Franz Josef Hospital with G.v. Preyer Children's Hospital, Department of Pediatrics, Vienna, Austria. ⁷Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. ⁸Neuromuscular Research Department, Medical University of Vienna, Centre for Anatomy and Cell Biology, Vienna, Austria. ⁹Psychiatric & Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ¹⁰The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ¹²Texas Children's Hospital, Houston, TX, USA. ¹³Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. ¹⁴Northern Finland Laboratory Centre NordLab and Medical Research Centre, Oulu University Hospital and University of Oulu, Oulu, Finland. ¹⁵Department of Pathology, Oulu University Hospital, Oulu, Finland. ¹⁶Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹⁷Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. ¹⁸Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki and Haartman Institute, Helsinki, Finland. ¹⁹Baylor Genetics, Houston, TX 77021, USA